Abstract The outbreak of COVID‐19 has become a serious public health emergency. The virus targets cells by binding the ACE2 receptor. After infection, the virus triggers in some humans an immune storm containing the release of proinflammatory cytokines and chemokines followed by multiple organ failure. Several vaccines are enrolled, but an effective treatment is still missing. Mesenchymal stem cells (MSCs) have shown to secrete immunomodulatory factors that suppress this cytokine storm. Therefore, MSCs have been suggested as a potential treatment option for COVID‐19. We report here that the ACE2 expression is minimal or nonexistent in MSC derived from three different human tissue sources (adipose tissue, umbilical cord Wharton`s jelly and bone marrow). In contrast, TMPRSS2 that is implicated in SARS‐CoV‐2 entry has been detected in all MSC samples. These results are of particular importance for future MSC‐based cell therapies to treat severe cases after COVID‐19 infection.
【저자키워드】 SARS‐CoV‐2, adult stem cells, cellular therapy, mesenchymal stromal cells (MSCs), TMPRSS2, 【초록키워드】 Treatment, Vaccine, Cytokine storm, therapy, Cytokines, Umbilical cord, Human, Infection, ACE2 receptor, Mesenchymal stem cells, MSCs, cytokine, chemokines, virus, chemokine, immune, COVID‐19, SARS‐CoV‐2, Bone marrow, outbreak, severe cases, target, public health emergency, multiple organ failure, proinflammatory cytokines, ACE2 expression, mesenchymal stem cell, binding, Adipose tissue, MSC, Trigger, Organ failure, triggers, followed by, in some, cell therapies, Proinflammatory cytokine, tissue, potential treatment option, Severe case, treat, COVID‐19 infection, adipose, immunomodulatory factors, effective, Cell, enrolled, shown, suggested, suppress, implicated, immunomodulatory factor, secrete, tissue source, umbilical, 【제목키워드】 ACE2, expression, stromal cell,